MEIP News and Press, MEI Pharma Inc. From 05/21/21

MEI Pharm (MEIP) says that new data from two phase 1 trials of its phosphatidylinositol 3-kinase delta ("PI3Kδ") inhibitor zandelisib showed strong response rates in lymphoma and malignancies.In one of the studies, all patients with relapsed/refractory indolent B-cell malignancies...

MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021 -Zandelisib, an investigational agent, +/- rituximab demonstrated 82% overall response rate in patients with relapsed or refractory (r/r) follicular l...

MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress PR Newswire SAN DIEGO and TOKYO , May 12, 2021 /PRNewswire/ -- MEI Pharma,...

MEI Pharma (MEIP): FQ3 GAAP EPS of -$0.28 misses by $0.12.Revenue of $2.42M (+95.2% Y/Y) misses by $2.99M.Adjusted net loss was $22.0M.Shares -0.9% AH.Press Release For further details see: MEI Pharma EPS misses by $0.12, misses on revenue

MEI Pharma Reports Third Quarter Fiscal 2021 Results and Operational Highlights -Topline TIDAL Study Data Evaluating Zandelisib in Relapsed or Refractory Follicular Lymphoma on Track to be Reported in the Fourth Quarter- - MEI Maintains Strong Financial Position with ~$164 M...

MEI Pharma (MEIP) announces that Richard Ghalie, senior vice president, clinical development, has been promoted as the company's chief medical officer.The company also announces that its current chief medical officer Robert Mass will retire on May 3, 2021.Ghalie is a hematologi...

MEI Pharma Announces the Retirement of Chief Medical Officer Robert Mass and Promotion of Richard Ghalie to Chief Medical Officer PR Newswire SAN DIEGO , April 30, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical comp...

Recent scientific research indicates that CDK9 inhibitors such as MEI Pharma's (MEIP) voruciclib may have an effect against KRAS solid tumors, according to a new research note from Wells Fargo.Analyst Nick Abbott writes that preclinical data presented by MEI at the American Association for Ca...

The following slide deck was published by MEI Pharma, Inc. in conjunction with this event. For further details see: MEI Pharma (MEIP) Presents At AACR Virtual Meeting 2021 - Slideshow

MEI Pharma and Kyowa Kirin Announce Completion of Patient Enrollment in Follicular Lymphoma Primary Efficacy Population of Global Phase 2 TIDAL Study Intended to Support Potential Accelerated Approval Application from U.S. Food and Drug Administration (FDA) Topline TIDAL Study D...